🔥Impact of baseline molecular alterations on efficacy of tucatinib + trastuzumab for HER2+, RAS WT mCRC #ESMO23
✅MOUNTAINEER phs-II 231 pts
👉cORR higher w/ greater HER2 amp.
👉Efficacy of TUC + Tras independent of GA in ERBB2, PIK3CA, APC, TP53 in RAS WT pts, but may be…

T:👉Yeni faz 2 çalışması, daha önce tedavi edilmiş safra yolu kanseri hastalarında Tucatinib ve trastuzumab'ın klinik etkinliğini gösterdi (objektif yanıt oranını %46,7 ). *

Bu sonuç, daha büyük çalışma ile doğrulanma ihtiyacı hissetse de HER2 pozitif safra yolu kanserleri için…

Para un tipo de cáncer de mama con metástasis existen fármacos como Abemaciclib y el Tucatinib con muy buenos resultados pero España se niega a financiarlos por su elevado coste…
Pero se despilfarra dinero en chuminadas y en tener contentas a las locas podemitas.
#TeamVox

7 Kasım 2023 Salı günü saat 12.30 'da Ali Furkan KIDIL'ın  ' HER2-Selective and Reversible Tyrosine Kinase updates Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer ' sunumuna katılımlarınızı bekliyoruz.
#universitemdeu

#HER2CLIMB02 trial
Important study in brain mets
#tucatinib #HER2positive #aBC #SABCS23
SABCS

Final Katherine Analysis.

- 7% of patients with residual disease treated with TDM1 will relapse in the brain as there first event.

-50% of all distant iDFS events!

Hoping Compass-RD adding tucatinib will lower this.

We still desperately need biomarkers of CNS relapse risk.

Tucatinib and Trastuzumab for Previously Treated HER2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

🔍30 patients

ORR➡️46.7%
mPFS➡️5.5 mo
1y OS➡️53.6%

Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Data from the GIM14/BIOMETA study brings light to the evolving treatment of HER2+ mBC showing remarkable mPFS⏱ boost w/ anti-HER2 agents in the last 20yrs. But challenges remain, especially for those w/ brain mets🧠.Emerging therapies like T-DXd & tucatinib hold promise🌟Quicker…

🔴 2/2.

Estos medicamentos están autorizados por la EMA y han de estar disponibles ya en España.

5-Luspatercept: (síndrome mielodisplásticos)
6-Mexiletina (mitonía)
7-Pertuzumab en combinación con TRASTUZUMAB (Cáncer de mama HER2+)
8-Tucatinib (Cáncer de mama HER2+)

Seguimos…

Tucatinib/trastuzumab in 2nd line metastatic HER2 + biliary tract cancer very positive in small phase 2 study #ASCO23

Great 🚨 news for patients with #HER2 (+) #ERBB2 amp BTC #BiliaryTractCancer Novel Tx options #tucatinib #trastuzumab #zanidatamab #ASCO23 congrats 🎉🎊 for the authors!

Tucatinib and trastuzumab in HER2+ biliary tract cancer:
🔹️46.7% ORR, 1 CR
🔹️Median DoR: 6 months
🔹️Median PFS and OS: 5.5 and 15.5 months, respectively.
🔹️Chemo-free regimen
Very encouraging!
#ASCO23 #hpbcsm #CancerResearch

Tucatinib & Trastuzumab for HER2 2+ Metastatic Biliary Tract Cancer
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
👉ORR 46.7%, mPFS 5.5 mo, mOS 15.5mo
👉very intersting data, more & more options for Her2+ BTC ->best strategy? 💊sequencing? Resistance mechanism?
ESMO - Eur. Oncology EASL Education ILCA…

Tucatinib & Trastuzumab for Previously Treated HER 2–Positive Metastatic Biliary Tract Cancer
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎SGNTUC-019, 30pts
👉ORR 46.7%, DCR 76.7%, PFS 5.5 mo, mOS 15.5 mo
🧐Consistent efficacy of HER2🎯💊in BTC
ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation…

SGNTUC-019 PhII basket of tucatinib + trastuzumab for pretreated w/>1 prior line #HER2 + adv BTC confirmed ORR 46.7% (1 CR, 13 PRs), DOR 6 mos, and median OS 15.5 mos #ASCO23 OncoAlert

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in HER2+ MBC

▶️PFS 4.7 mo
▶️OS 13.4 mo
▶️ORR 32.6%
#bcsm #JAMA
jamanetwork.com/journals/jaman…

Targeting Her2 amplified #chlolangiocarcinoma two different ways 👍

Dr. Yoshiaki Nakamura presented 30 patients treated with tucatinib and trasruzumab
👉46.7% ORR - wonderful‼️

10/14
What next...?
foxtrot-study Platform Yorkshire Cancer Research
OPEN IN UK
👍FOxTROT 2 - NAC in older pts
👍FOxTROT 3 - NAC with mFOLFOXIRI
COMING SOON
👍 FOxTROT 4 - Enco/Cetux in BRAF-mut pts
👍FOxTROT HER2 - Tucatinib/Tras in HER2 +ve pts
👍FOxTROT-IO - watch for news soon 😉

HER2CLIMB-02: T-DM1+/- tucatinib in mHER2+ BC presented by Sara Hurvitz

43% with brain mets
64% 1 prior line, 16% 2 prior lines
89% prior pertuzumab
mPFS 9.5 vs 7.4 mo
mPFS in pts with brain mets: 7.8 mo vs 5.7 mo

#SABCS23 OncoAlert

Tucatinib plus TDM1 vs TDm1 alone
. Her2climb02 . Useful PFS benifit , especially in patients with brain mets. No OS benfit. Hr 1.23 . Can be used in those with Brain mets . SABCS OncoAlert #SABCS23